Search Results

You are looking at 291 - 300 of 493 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

New Developments in Thyroid Cancer

Robert I. Haddad

. Dr. Haddad noted, “we routinely use concurrent chemoradiotherapy in patients who undergo a complete surgical resection and our preferred regimen is weekly carboplatin and paclitaxel. Refer these patients immediately for a clinical trial if one is

Full access

Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer

Rogerio A. Lilenbaum and Leora A. Horn

/or honoraria from Genentech, Inc. and Merck & Co., Inc. References 1. Mok TS Wu YL Thongprasert S . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma . N Engl J Med 2009 ; 361 : 947 – 957 . 2. Yang JC Wu YL Schuler M

Full access

Does Chemoradiation Benefit Patients With Gastric Cancer Managed Without Surgery?

Kimberly L. Johung and Stacey M. Stein

, with concurrent fluorouracil and paclitaxel. A pathologic CR was achieved in 26% of patients, with improved survival in these patients. 11 The ongoing phase III TOPGEAR trial is evaluating the addition of preoperative CRT to perioperative chemotherapy

Full access

Multimodality Approaches to Localized Gastric Cancer

Prajnan Das, Yixing Jiang, Jeffrey H. Lee, Manoop S. Bhutani, William A. Ross, Paul F. Mansfield, and Jaffer A. Ajani

2 cycles of 5-FU, paclitaxel, and cisplatin, followed by radiotherapy with concurrent paclitaxel and infusional 5-FU, with 40 patients then undergoing surgery. 47 This study showed a pathologic complete response rate of 20%, R0 resection rate of 78

Full access

Controversies in the Surgical Management of Gastric Cancer

David A. Kooby and Daniel G. Coit

, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: Interim report . Br J Cancer 1989 ; 60 : 739 – 744 . 55 Kelsen DP Schwartz G Janjan N Minsky B . A randomized phase II comparison of two cisplatin-paclitaxel

Full access

Principles and Techniques of Radiation Therapy for Esophageal and Gastroesophageal Junction Cancers

Lisa Hazard, Gary Yang, Mary Frances McAleer, James Hayman, and Christopher Willett

: a randomized phase II study of two paclitaxel-based chemoradiotherapy regimens . Available at : . Accessed 3 September 2008 . 13. Tachibana M Kinugasa S Yoshimura H . Clinical

Full access

Crescendos and Decrescendos: Gastric and Esophageal Cancers

Jaffer A. Ajani

Dutch trial 15 that randomly assigned 363 patients to receive either chemoradiation (paclitaxel plus carboplatin with 40 Gy of radiation) and surgery (n = 175) or surgery alone (n = 188), patients who received preoperative chemoradiation had

Full access

The Abu Dhabi Declaration: Why the Hustle?

Hamdy A. Azim, Abdul-Rahman Jazieh, and Mohammad Jahanzeb

of non-small-cell lung cancer to gefitinib . N Engl J Med 2004 ; 350 : 2129 – 2139 . 4. Mok TS Wu YL Thongprasert S . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma . N Engl J Med 2009 ; 361 : 947 – 957 . 5

Full access


initial testing for all patients. It also includes a number of new recommendations for primary chemotherapy, maintenance treatment, and recurrence treatment. The weekly paclitaxel/carboplatin regimen is a new primary chemotherapy option for all stages

Full access

Part 2: Abstracts from the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™

%), and ovarian (7%). Hematologic malignancies constituted 11% of the cohort. Single-agent chemotherapy regimens were most common (233 requests), with docetaxel, paclitaxel, gemcitabine, pemetrexed, and fluorouracil totaling 125 requests. Combination